How to Evaluate a Pharmaceutical Contract Testing Quote (Without Getting Burned)

Most “bad lab experiences” started as a fuzzy quote

Pharmacies rarely regret choosing a slightly more expensive competent lab. They regret choosing a cheap quote that quietly excluded suitability work, rush handling, identification, or investigation support.

This guide gives compounding and specialty pharmacy teams a repeatable process to evaluate pharmaceutical contract testing laboratory (CTL) quotes—especially for USP microbiology and chemistry methods.

Step 1: Write the brief before you invite bids

A strong brief includes:

• Test(s) requested (e.g., USP <71>, <85>, <61>/<62>, potency assay)
• Product matrix and special handling
• Sample quantity available
• Documentation required
• Due date / clinical urgency
• Shipping constraints
• Whether this is one-off, monthly, or annual volume

Send the same brief to every lab. Otherwise you are comparing different jobs.

On LabCompare Rx, attach that brief when you request a quote so labs respond to the same scope.

Step 2: Qualify before you price-shop

Build a must-pass gate:

• Method capability publicly credible
• Accreditation scope fit (ISO/IEC 17025 / A2LA where relevant)
• Acceptable receiving logistics
• Willingness to discuss suitability / method confirmation
• Professional response to your brief (speed alone is not competence)

Disqualify early. Pricing unqualified labs wastes weeks.

Step 3: Demand a scope-complete quote

Your comparison sheet should force clarity on:

1. Base analytical fee
2. Suitability / onboarding fees for new products
3. Rush multipliers and what they change operationally
4. Retest policy (lab error vs product failure)
5. ID fees (for EM or failure investigations)
6. Report package included vs à la carte
7. Sample return / disposal fees
8. Minimums and cancellation terms

If a quote is a single number with no assumptions, ask for an itemized revision.

Step 4: Separate calendar TAT from marketing TAT

Ask labs to timestamp:

• Receipt → accessioning
• Accessioning → assay start
• Assay start → data review
• Review → CoA release

For incubation-based methods, confirm that “5 days TAT” does not mean “we incubate for fewer days than required.”

Step 5: Score with a weighted matrix (example)

Use weights that match your risk:

Criterion	Example weight
Scope / accreditation fit	25%
Method & matrix experience	20%
Communication / investigation SLA	15%
Logistics & accessioning quality	15%
Documentation quality	10%
Price (complete scope)	15%

Adjust weights for your organization—but write them down before opening price emails to reduce bias.

Step 6: Run a pilot when the risk justifies it

For new sterility, endotoxin, or potency partners, a pilot lot (or parallel testing against your incumbent) is cheaper than a recall-scale mistake. Define success criteria in advance: on-time CoA, clear narrative, clean chain of custody, no surprise invoices.

Hidden failure modes to watch

• Bait-and-switch site: sales team in one state, performing lab in another with weaker controls
• Subcontracting without disclosure
• Verbal rush promises not reflected on the quote
• “Includes everything” language that excludes suitability in the footnotes
• Portal-only reports with no audit-friendly PDF archive

Quality agreement basics (even for small pharmacies)

You do not need a 40-page MSA to start, but you do need written alignment on:

• Confidentiality
• Notification of failures / invalids
• Change control for methods
• Record retention
• Contacts and escalation
• How disputes over lab error are handled

Attach the final quote exhibits to the agreement so scope does not drift.

How LabCompare Rx fits this process

LabCompare Rx is built for the shortlist → quote → decision loop:

• Search by USP chapter and credentials
• Open clear lab listings (no invented prices on unclaimed profiles)
• Request quotes from pharmacies
• Claimed labs can respond in-app; admins can help intros for unclaimed listings

That keeps procurement grounded in real capabilities instead of scraped “average price” fiction.

Negotiation without compromising quality

Once two labs clear your technical bar, commercial conversation is appropriate:

• Ask about volume tiers if you will send monthly work
• Bundle related methods (for example <71> + <85>) for operational simplicity
• Confirm whether method onboarding fees are one-time
• Avoid negotiating away investigation notifications or raw-data access

If a lab will only win on price by removing suitability or weekend accessioning you need, that is not a discount—it is a different (worse) service.

Involving the pharmacist-in-charge and QA early

Procurement-only decisions create downstream CAPA pain. Before approving a vendor:

• PIC / quality reviews the method fit
• Operations confirms shipping feasibility
• Finance confirms the complete cost model
• Someone owns ongoing vendor performance review (OTIF CoAs, investigation quality)

Put that RACI in your vendor SOP even if your team is small.

When to re-bid

Re-evaluate when:

• Your product mix changes materially
• TAT performance drifts for 2–3 months
• Accreditation scope changes or lapses
• Communication quality declines
• Volume grows enough to justify a primary/secondary dual-source strategy

Dual-sourcing critical release tests is often worth the administrative cost.

Checklist you can copy into your QMS

• Test brief finalized
• 3 qualified labs identified
• Scopes filed
• Itemized quotes received
• Weighted score completed
• Pilot criteria defined (if needed)
• Quality agreement signed
• Vendor approved in QMS
• Performance metrics assigned to an owner

Bottom line

A pharmaceutical testing quote is a mini protocol plus a commercial offer. Evaluate it like QA, not like office-supply shopping. Scope completeness, accreditation fit, and investigation behavior usually matter more than a small unit-price gap.

When you are ready for the next bid set, build your shortlist on LabCompare Rx and send one clean brief to every candidate.